Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression

Antiviral Research

Volumn 91, Issue 1, 2011, Pages 72-80

  Dower, Ken ^a,b   Rubins, Kathleen H ^a   Hensley, Lisa E ^c   Connor, John H ^b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral; Drug discovery; Gene expression; High throughput; Orthopoxvirus

Indexed keywords

FLUORESCENT PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTENT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MONITORING; NONHUMAN; PLASMID; PRIORITY JOURNAL; VACCINIA VIRUS; VIRAL PHENOMENA AND FUNCTIONS; VIROGENESIS;

ANIMALS; CERCOPITHECUS AETHIOPS; CRICETINAE; DNA, VIRAL; FLUORESCENT DYES; GENE EXPRESSION; GENES, REPORTER; HUMANS; PROMOTER REGIONS, GENETIC; VACCINIA; VERO CELLS; VIRUS PHYSIOLOGICAL PHENOMENA;

ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA; VARIOLA VIRUS;

EID: 79957637174     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.04.014     Document Type: Article

References (32)

1. Baldick C.J., Keck J.G., Moss B. Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate-class promoters. J. Virol. 1992, 66:4710-4719.
2. Baldick C.J., Moss B. Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes. J. Virol. 1993, 67:3515-3527.
3. Bertholet C., Van Meir E., ten Heggeler-Bordier B., Wittek R. Vaccinia virus produces late mRNAs by discontinuous synthesis. Cell 1987, 50:153-162.
4. Black E.P., Condit R.C. Phenotypic characterization of mutants in vaccinia virus gene G2R, a putative transcription elongation factor. J. Virol. 1996, 70:47-54.
5. Broyles S.S. Vaccinia virus transcription. J. Gen. Virol. 2003, 84:2293-2303.
6. Broyles S.S., Li J., Moss B. Promoter DNA contacts made by the vaccinia virus early transcription factor. J. Biol. Chem. 1991, 266:15539-15544.
7. Corish P., Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng. 1999, 12:1035-1040.
8. Dhar A.D., Werchniak A.E., Li Y., Brennick J.B., Goldsmith C.S., Kline R., Damon I., Klaus S.N. Tanapox infection in a college student. N. Engl. J. Med. 2004, 350:361-366.
9. Hammarlund E., Lewis M.W., Carter S.V., Amanna I., Hansen S.G., Strelow L.I., Wong S.W., Yoshihara P., Hanifin J.M., Slifka M.K. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 2005, 11:1005-1011.
10. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 2003, 9:1131-1137.
11. Hansen S.G., Cope T.A., Hruby D.E. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance. Biotechniques 2002, 32:1182-1187. pp. 1178, 1180.
12. Hung J.J., Chung C.S., Chang W. Molecular chaperone Hsp90 is important for vaccinia virus growth in cells. J. Virol. 2002, 76:1379-1390.
13. Johnson M.C., Damon I.K., Karem K.L. A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. J. Virol. Methods 2008, 150:14-20.
14. Keck J.G., Baldick C.J., Moss B. Role of DNA replication in vaccinia virus gene expression: a naked template is required for transcription of three late trans-activator genes. Cell 1990, 61:801-809.
15. Li X., Zhao X., Fang Y., Jiang X., Duong T., Fan C., Huang C.C., Kain S.R. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 1998, 273:34970-34975.
16. McFadden G. Poxvirus tropism. Nat. Rev. Microbiol. 2005, 3:201-213.
17. Moss B. Poxviridae: The Viruses and Their Replication 2007, vol. 2. Lippincott Williams & Wilkins, Philadelphia.
18. Nagai T., Ibata K., Park E.S., Kubota M., Mikoshiba K., Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat. Biotechnol. 2002, 20:87-90.
19. Parker S., Nuara A., Buller R.M., Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007, 2:17-34.
20. Popov S., Mirshahidi S., Essono S., Song R., Wang X., Ruprecht R.M. Generation of recombinant vaccinia viruses via green fluorescent protein selection. DNA Cell Biol. 2009, 28:103-108.
21. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A., Swain G.R., Olson V.A., Sargent E.K., Kehl S.C., Frace M.A., Kline R., Foldy S.L., Davis J.P., Damon I.K. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 2004, 350:342-350.
22. Satheshkumar P.S., Anton L.C., Sanz P., Moss B. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 2009, 83:2469-2479.
23. Schwer B., Visca P., Vos J.C., Stunnenberg H.G. Discontinuous transcription or RNA processing of vaccinia virus late messengers results in a 5′ poly(A) leader. Cell 1987, 50:163-169.
24. Slifka M.K. The future of smallpox vaccination: is MVA the key?. Med. Immunol. 2005, 4:2.
25. Smith S.K., Olson V.A., Karem K.L., Jordan R., Hruby D.E., Damon I.K. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob. Agents Chemother. 2009, 53:1007-1012.
26. Subach O.M., Gundorov I.S., Yoshimura M., Subach F.V., Zhang J., Gruenwald D., Souslova E.A., Chudakov D.M., Verkhusha V.V. Conversion of red fluorescent protein into a bright blue probe. Chem. Biol. 2008, 15:1116-1124.
27. Teale A., Campbell S., Van Buuren N., Magee W.C., Watmough K., Couturier B., Shipclark R., Barry M. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J. Virol. 2009, 83:2099-2108.
28. Villa N.Y., Bartee E., Mohamed M.R., Rahman M.M., Barrett J.W., McFadden G. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology 2010, 401:266-279.
29. Ward B.M., Moss B. Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J. Virol. 2001, 75:4802-4813.
30. Whitley R.J. Smallpox: a potential agent of bioterrorism. Antiviral Res. 2003, 57:7-12.
31. Xiang Y., Simpson D.A., Spiegel J., Zhou A., Silverman R.H., Condit R.C. The vaccinia virus A18R DNA helicase is a postreplicative negative transcription elongation factor. J. Virol. 1998, 72:7012-7023.
32. Yuen L., Moss B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc. Natl. Acad. Sci. USA 1987, 84:6417-6421.